Coronavirus
AstraZeneca Declares Q1 Sales Of $275 Million

The British Pharma giant, AstraZeneca, reported last week, sales talking $275 Million for the opening financial quarter, despite facing legal action by the European Union over delivery shortfalls that are hampering innovation efforts in its largest market.
The firm has delivered nearly 70 million doses of vaccine which, it co-developed with Oxford University and, they have been instrumental in the rapid vaccination drives across the UK.
Defending AstraZeneca against the charges by the EU its CEO, Pascal Soriot stated, “I don’t think we ever overpromised…more than we thought we could deliver. What we communicated at the time was based on the capacity we had put together”, he was insistent that there were no regrets.
The EU has AstraZeneca as its second-largest vaccine supplier, right behind the US giant Pfizer, with AstraZeneca having $224 Million worth of Sales in its largest market.
The EU is undertaking legal action on the basis of, breach of an advanced purchase agreement. A charge that AstraZeneca outright dismissed and vowed to fight it out in the courts.
AstraZeneca had promised to deliver 50 Million doses to Europe by the end of April but, the EU contests that the amount is far lower than what should have been delivered.
-
Economy2 months ago
Is Gold a Good Investment in 2025? A Deep Dive into the Precious Metal’s Future
-
OER Magazines2 months ago
OER, March 2025
-
Alamaliktistaad Magazines2 months ago
Al-Iktisaad, March 2025
-
News2 months ago
Nothing Phone 3a and 3a Pro launches in the Middle East
-
Automotive1 month ago
South Korea Plans to Support Auto Sector with US$2B Following US Tariffs
-
News1 month ago
Oman Oil Prices Witness Drop Amid Shifting Global Trade Dynamics
-
News1 month ago
Aligning HR Strategies with Oman Vision 2040: A Roadmap for Organisational Growth – OER Business Summit 2025
-
News2 months ago
Omantel Partners with TeKnowledge to Enhance Employee Skills in AI & Data Science